洛铂与顺铂分别联合替吉奥治疗晚期转移性乳腺癌的疗效比较

Comparison of Therapeutic Efficacy of Lobaplatin or Cisplatin Combined with Tegafur,Gimeracil and Oteracil Potassium in the Treatment of Advanced Metastatic Breast Cancer

目的:比较洛铂与顺铂分别联合替吉奥治疗晚期转移性乳腺癌的临床疗效与安全性。方法:160例晚期转移性乳腺癌患者随机分为观察组和对照组,每组80例。对照组患者给予注射用顺铂30 mg/m^2,静脉滴注,每3周1次+替吉奥胶囊50 mg,饭后口服,每日2次,连服14 d。观察组患者给予注射用洛铂30 mg/m^2,静脉滴注,每3周1次+替吉奥胶囊(用法用量同对照组)。每3周为1个周期,两组均治疗2个周期。观察并比较两组患者近期疗效[客观有效率(ORR)、疾病控制率(DCR)],淋巴结、肺部、肝脏、骨组织的转移病灶化疗效果、化疗不良反应发生情况和远期疗效等。结果:治疗后观察组患者ORR(67.50%vs.46.25%)、DCR(85.00%vs.66.25%)、淋巴结转移ORR(71.43%vs.47.83%)、肺部转移ORR(60.71%vs.40.00%)和DCR(78.57%vs.56.00%)、骨组织转移ORR(28.57%vs.16.67%)、1年生存率(75.00%vs.52.50%)和2年生存率(42.50%vs.17.50%)均显著高于对照组;化疗不良反应发生率显著低于对照组(43.75%vs.70.00%),差异均有统计学意义(P<0.05)。两组患者淋巴结转移DCR、骨组织转移DCR、肝脏转移ORR和DCR、半年生存率比较,差异均无统计学意义(P>0.05)。结论:与顺铂联合替吉奥相比,洛铂联合替吉奥治疗晚期转移性乳腺癌的近期疗效,淋巴结转移、骨组织转移、肺部转移治疗效果,1年以上远期治疗效果和安全性均较好,而两者肝脏转移治疗效果相当。

OBJECTIVE ： To compare therapeutic efficacy and safety of lobaplatin or cisplatin combined with tegafur, gimeracil and oteracil potassium in the treatment of advanced metastatic breast cancer. METHODS： A total of 160 patients with advanced met- astatic breast cancer were randomly divided into observation group and control group, with 80 cases in each group. Control group was given Cisplatin injection 30 mg/m2 intravenously, every 3 weeks Tegafur, Gimeracil and Oteracil Potassium capsules 50 mg orally after meal, twice a day, for consecutive 14 days. Observation group was given Lobaplatin for injection 30 mg/m2 intravenous- ly, every 3 weeks＋Tegafur, Gimeracil and Oteracil Potassium capsules （same usage and dosage as control group）, every 3 weeks. A treatment course lasted for 3 weeks, and both groups received 2 courses. Short-term efficacies （ORR, DCR）, chemotherapy effects of lymph node, lung, bone and liver, ADR and long-term efficacy were compared between 2 groups. RESULTS ： After treatment, ORR（67.50% vs. 46.25% ）,DCR（85.00% vs. 66.25%）,ORR of lymph node metastasis （71.43% vs. 47.83%）, ORR of lung me- tastasis （60.71% vs. 40.00% ）, DCR of lung metastasis （78.57% vs. 56.00% ）, ORR of bone metastasis （28.57% vs. 16.67% ）, 1-year survival rates （75.00% vs. 52.50% ） and 2-years survival rates （42.50% vs. 17.50% ） of observation group were significant- ly higher than control group; the incidence of chemotherapy ADR in observation group was significantly lower than control group （43.75% vs. 70.00% ）, with statistical significance （P〈0.05）. There was no statistical significance in lymph node metastasis DCR, bone tissue metastasis DCR, liver metastasis ORR and DCR, or half year sarvival rate between 2 groups （P〉0.05）. CONCLU- SIONS： Compared to cisplatin combined with tegafur, gimeracil and oteracil potassium, lobaplatin combined with tegafur, gimeracil and oteracil potassium show better short-term therapeutic efficacy, therapeutic efficacy of lymph node metastasis, bone metastasis and lung metastasis,more than 1-year long-term therapeutic efficacy and safety in the treatment of advanced metastatic breast cancer.